Pharmaxis appoints Edward Rayner Non-Executive Director

Company News

by Anna Napoli

Pharmaceutical research company, Pharmaxis (ASX:PXS) has today announced the appointment of Edward Rayner as a non-executive director of the company.

He is currently an investment director at Arix Bioscience a global healthcare and life science company.

Arix holds 11 per cent in Pharmaxis following the recent share placement.

Prior to joining Arix Mr Rayner spent 18 years as an equity analyst and portfolio manager in Europe and Australia.

Pharmaxis says Mr Rayner's global experience as a specialist biotech investor is very relevant to the company.

Shares in Pharmaxis (ASX:PXS) closed flat at 31.5 cents yesterday.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.